AWM
CLDI icon

Axxcess Wealth Management’s Calidi Biotherapeutics CLDI Stock Holding History

Axxcess Wealth Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-110
Closed -$19.9K – 877
2023
Q4 		$19.9K Buy
+110
New +$29.5K ﹤0.01% 826

Other funds holding CLDI

RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $315M AUM 19.93% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Axxcess Wealth Management's CLDI Position: Q1 2024 in Review

Axxcess Wealth Management sold out of Calidi Biotherapeutics (CLDI) in Q1 2024, closing a stake of 110 shares — an estimated $19.9K sold.

Axxcess Wealth Management first reported a position in CLDI in Q4 2023 and held it in 1 quarter. The position peaked at $19.9K in Q4 2023. 30 funds tracked by Wall St. Rank hold CLDI as of Q1 2024.

  • Axxcess Wealth Management reported no remaining Calidi Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Axxcess Wealth Management sold 110 Calidi Biotherapeutics shares in Q1 2024, an estimated $19.9K.
  • Axxcess Wealth Management first reported a position in Calidi Biotherapeutics in Q4 2023 and held it in 1 quarter.
  • Axxcess Wealth Management's Calidi Biotherapeutics position peaked at $19.9K in Q4 2023.
  • 30 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2024.

Based on Axxcess Wealth Management's 13F filing for Q1 2024, filed 14 May 2024.